"Name Your Price": What JPM Week Revealed About Biotech's Liquidity Shift

I heard “name your price” more times at JPM last week than in my entire career.

That phrase used to mean abundance, the power top startups had over investors. This year, it meant the opposite.

All week I heard speculation about deals that weren’t happening. Selective leaks. Rumor-driven narratives.

But no major announcements.

For genuinely innovative companies, “name your price” revealed a harder truth: very few investors remain structurally able to underwrite real innovation.

What I saw all week:

→ Derisked assets are the focus. Late-stage funds are pushed toward lower-risk, later-stage bets. Traditionally early-stage investors have been pressured to follow. Innovation capital exists, but it’s narrow.

→ Everyone is chasing the same targets. Pattern-matching off recent exits moved fast. Outside those lanes, processes slowed to a crawl.

→ Silence became the signal. The lack of announced deals showed how few buyers currently have both conviction and mandate.

As an investor, I didn’t attend JPM expecting fireworks or headline deals.

After a full week of meetings, my view hasn’t changed.

Innovation isn’t short on ideas or quality companies. It’s short on investors who can still price risk and move with conviction.